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Galactosemia is a metabolic disorder caused by mutations in the GALT
gene [1,2]. We encountered a patient heterozygous for a known
pathogenic H132Q mutation and a novel S222N variant of unknown
signiﬁcance [3]. Reminiscent of patients with the S135L mutation, our
patient had loss of GALT enzyme activity in erythrocytes but a very
mild clinical phenotype [3–8]. We performed splicing experiments and
computational structural analyses to investigate the role of the novel
S222N variant. Alamut software data predicted loss of splicing
enhancers for the S222N and S135L mutations [9,10]. A cDNA library
was generated from our patient's RNA to investigate for splicing errors,
but no change in transcript length was seen [3]. In silico structural
analysis was performed to investigate enzyme stability and attempt to
understand the mechanism of the atypical galactosemia phenotype.
Stability results are publicly available in the GALT Protein Database 2.0
[11–14]. Animations were created to give the reader a dynamic view ofier Inc. This is an open access article under the CC BY license
/j.ymgmr.2014.12.004
ochester.edu (B. Cocanougher).
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(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations tableSubject area MedicineMore speciﬁc
subject areaMedical genetics, galactosemiaType of data Graph, protein structure animation, pdb ﬁles, python scripts
How data was
acquiredIn silico structural analyses performed with Chimera (UCSF) and modeller programs. Splicing studies
performed with Alamut Splicing Predictor (Cold Spring Harbor Laboratories). RNA studies performed
on whole blood sample from patient.Data format Analyzed molecular data, Analyzed computational data, and raw.pdb ﬁles for structural analysis
Experimental factors Computational analyses were performed using Alamut software, Modeller, and UCSF Chimera.
Experimental
featuresSplicing enhancer studies performed using Alamut software. Animations and structural analysis
performed with Modeller and UCSF Chimera software.Data source location Not applicable
Data accessibility Structural data available in GALT protein database (GALT Protein Database 2.0). Biochemical data
available in article.Harbor Laboratories) Splicing Effects window around the GALT c665G4A
sequence, with a G at position c.665, and the bottom panel representing the
els the nucleotides boxed in lavender represent the 30 end of exon 7. The
roy a predicted splice site.
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GAL
rep
exo
redHeterozygosity for novel S222N GALT mutation leads to atypical galactosemia similar to known
S135L cases. Splicing enhancers are predicted to be lost for both S222N and S135L mutations. In silico analyses predict stability/instability of dimers present in our patient and allow for
visualization of mutation types.1. Data, experimental design, materials and methods
1.1. Case report
Our data is based on a single case of atypical galactosemia caused by compound heterozygosity for
a known pathogenic H132Q mutation and a novel S222N variant of unknown signiﬁcance [3]. Brieﬂy,
our patient had a positive newborn screen for galactosemia with subsequent biochemical. 2. Screenshot from the Alamut (Cold Spring Harbor Laboratories) Splicing Predictor/ESE Predictions window around the
T c665G4A variant [9,10]. The top box represents the wild type sequence, with a G at position c.665, and the bottom panel
resenting the mutant sequences, with an A at c.665. In both panels the nucleotides boxed in lavender represent the 30 end of
n 7. The mutant sequence is predicted to lose binding sites for SRp40 (green box), SRp55 (yellow box), and SF2/ASF (pink/
box).
B. Cocanougher et al. / Data in Brief 3 (2015) 34–39 37conﬁrmation of absent GALT enzyme activity, was treated with a galactose-restricted diet until the age
of 3 with no symptoms, and was later lost to follow-up. The patient presented to our clinic at age 17
with no stigmata of galactosemia (apart from mild anxiety) to determine his disease status [15].
Testing revealed nearly complete absence of GALT enzyme activity in erythrocytes without any
increase in the clinical biomarkers of galactosemia, galactose-1-phosphate and galactitol [16,17].
Sequencing revealed compound heterozygosity for H132Q and S222N mutations.
Given the ability of our patient to oxidize galactose in tissues other than red blood cells, as
evidenced by galactose-1-phosphate and galactitol levels in the normal range, we suspected a splicing
defect. Differential splicing seemed a reasonable explanation for differential tissue activity of the GALT
enzyme.1.2. Splicing experiments
We ﬁrst examined the S222N mutation for changes in splice sites due to genomic c.665G4A. Fig. 1
is a screenshot of the Alamut software program showing that this mutation does not create or destroy
a predicted splice site [9,10].
Though this mutation does not directly lead to changes in a splice site, further investigation
revealed a predicted loss of a cluster of exonic splicing enhancer (ESE) sites due to the c.665G4A
mutation (Fig. 2). This could potentially explain the loss of activity only in erythrocytes if these
enhancers were speciﬁc to red blood cells and unused in other tissues. Interestingly, the c.404C4T
mutation, which leads to the S135L protein, also results in a predicted loss of ESE clusters (Fig. 3).
In order to further investigate this hypothesis, RNA was isolated from the whole blood sample, a cDNA
library was created, and PCR was used to amplify the entire gene in several overlapping pieces. No shift in
cDNA size was seen, which would be expected in the case of interrupted or aberrant splicingFig. 3. Screenshot from the Alamut (Cold Spring Harbor Laboratories) Splicing Predictor/ESE Predictions window around the
GALT c.404 C4T variant responsible for the S135L mutation [8,9]. The top box represents the wild type sequence, with a G at
position c.665, and the bottom panel representing the mutant sequences, with an A at c.665. In both panels the nucleotides
boxed in lavender represent the 30 end of exon 7. The mutant sequence is predicted to lose binding sites for SF2/ASF (pink/
red box).
Fig. 4. Video stills of two movies generated to examine the structure of GALT enzyme variants. Supplementary Movie
1 examines the location and neighboring residues for the H132Q/S222N heterodimer. Supplementary Movie 2 examines the
location of the S222N and S135L mutation residues.
B. Cocanougher et al. / Data in Brief 3 (2015) 34–3938(Supplementary Fig.1) [3]. The cDNAwas sequenced to look for splicing defects that may not be apparent on
gel electrophoresis, but there were no changes in exon structure from the reference or the father's cDNA
sequence (Supplementary Fig. 2) [3]. The only base pair change identiﬁed was the c.665G4A variant itself.1.3. Structure analysis
Protein modeling was performed to evaluate the stability of the three types of dimers produced by
our patient (H132Q homodimer, H132Q/S222N heterodimer, and S222N homodimer) and the
phenotypically similar S135L homodimer (Supplementary Files 1–4). We submitted our mutation to
the GALT protein database run by Dr. Anna Marabotti and the Laboratory of Bioinformatics at the
Institute of Food Science. The models were mutated using the “mutate model” function in Modeller.
Data on stability of each of the various GALT dimers are are accessible in the GALT Protein Database 2.0
[11,12].
Using the UCSF Chimera software, we investigated the residues involved in our four dimeric structures.
As evidenced in the included animations, the mutations in the H132Q and S222N heterodimer are too far
from one another in the structure to interact directly (Supplementary Movie 1) (Fig. 4).
A separate analysis was performed to visualize the S222N and S135L residue locations. The two are
located on separate ends of the dimer, but both appear to be peripherally accessible for
phosphorylation in the non-mutated state (Supplementary Movie 2). This animation was colored to
match the original publication of the GALT enzyme structure [18]. Python scripts created to generate
both of the animations above have been included (Supplementary Files 5,6). They can be opened and
modiﬁed using the UCSF Chimera software [14].Appendix A. Supplementary information
Supplementary data associated with this article can be found in the online version at http://dx.doi.
org/10.1016/j.dib.2015.01.001.References
[1] J.L. Fridovich-Keil, J.H. Walter, Galactosaemia, in: D. Valle, B. Vogelstein, K.W. Kinzler, S.E. Antonarakis, A. Ballabio, et al.,
(Eds.), The Online Metabolic and Molecular Bases of Inherited Disease, OMMBID, Part 7: Carbohydrates, McGraw Hill, New
York 2008, p. 2008. (Chapter 72).
B. Cocanougher et al. / Data in Brief 3 (2015) 34–39 39[2] A.M. Bosch, L. Ijlst, W. Oostheim, J. Mulders, H.D. Bakker, F.A. Wijburg, R.J. Wanders, H.R. Waterham, Identiﬁcation of novel
mutations in classical galactosemia, Hum. Mutat. 25 (5) (2005) 502.
[3] B. Cocanougher, U. Aypar, A. McDonald, L. Hasadsri, M.J. Bennett, W.E. Highsmith, K. D'Aco, Compound heterozygosity with
a novel S222N GALT mutation leads to atypical galactosemia with loss of GALT activity in erythrocytes but little evidence of
clinical disease, Mol. Genet. Metab. Rep. (2014).
[4] L. Baker, W.J. Mellman, T.A. Tedesco, S. Segal, Galactosemia: symptomatic and asymptomatic homozygotes in one Negro
sibship, J. Pediatr. 68 (1966) 551–558.
[5] S. Segal, P. Cuatrecasas, The oxidation of C 14 galactose by patients with congenital galactosemia, Am. J. Med. 44 (1968)
340–347.
[6] S. Segal, S. Rogers, P.G. Holtzapple, Liver galactose-1-phosphate uridyl transferase: activity in normal and galactosemic
subjects, J. Clin. Invest. 50 (1971) 500–506.
[7] K. Lai, S.D. Langley, R.H. Singh, P.P. Dembure, L.N. Hjelm, L.J. Elsas, A prevalent mutation for galactosemia among black
Americans, J. Pediatr. 128 (1) (1996) 89–95.
[8] N. Manga, T. Jenking, H. Jackson, D.A. Whittaker, A.B. Lane, The molecular basis of transferase galactosaemia in South African
negroids, J. Inherit. Metab. Dis. 22 (1) (1999) 37–42.
[9] P.J. Smith, C. Zhang, J. Wang, S.L. Chew, M.Q. Zhang, A.R. Krainer, An increased speciﬁcity score matrix for the prediction of
SF2/ASF-speciﬁc exonic splicing enhancers, Hum. Mol. Genet. 15 (16) (2006) 2490–2508.
[10] L. Cartegni, J. Wang, Z. Zhu, M.Q. Zhang, A.R. Krainer, ESEﬁnder: a web resource to identify exonic splicing enhancers, Nucl.
Acid Res. 31 (13) (2003) 3568–3571.
[11] A. Marabotti, A.M. Facchiano, Homology modeling studies on human galactose-1-phosphate uridylyltransferase and on its
galactosemia-related mutant Q188R provide an explanation of molecular effects of the mutation on homo- and
heterodimers, J. Med. Chem. 48 (2005) 773–779.
[12] A. d'Acierno, A. Facchiano, A. Marabotti, GALT protein database: querying structural and functional features of GALT
enzyme, Hum. Mutat. 35 (2014) 1060–1067, http://dx.doi.org/10.1002/humu.22613.
[13] N. Eswar, M.A. Marti-Renom, B. Webb, M.S. Madhusudhan, D. Eramian, M. Shen, U. Pieper, A. Sali, Comparative protein
structure modeling with MODELLER, Current Protocols in Bioinformatics, John Wiley & Sons, Inc., 2006 (Supplement 15,
5.6.1-5.6.30).
[14] E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, T.E. Ferrin, UCSF Chimera—a visualization
system for exploratory research and analysis, J. Comput. Chem. 25 (13) (2004) 1605–1612.
[15] S.E. Waisbren, N.L. Potter, C.M. Gordon, R.C. Green, P. Greenstein, C.S. Gubbels, E. Rubio-Gozalbo, D. Schomer, C. Welt,
V. Anatasoaie, The adult galactosemic phenotype, J. Inherit. Metab. Dis. 35 (2) (2012) 279–286.
[16] G.T. Berry, I. Nissim, L. Zhiping, A.T. Mazur, J.B. Gibson, S. Segal, Endogenous synthesis of galactose in normal men and
patients with hereditary galactosaemia, Lancet 346 (1995) 1073–1074.
[17] C. Jakobs, S. Schweitzer, B. Dorland, Galactitol in galactosemia, Eur. J. Pediatr. 154 (Suppl. 2) (1995) S50–S52.
[18] J.E. Wedekind, P.A. Frey, I. Rayment, Three-dimensional structure of galactose-1-phosphate uridylyltransferase from
Escherichia coli at 1.8 A resolution, Biochemistry 34 (1995) 11049–11061.
